Skip to main content
Partnerships to advance development of CRISPR-Cas9 CAR-T therapies

Mustang Bio has entered a research collaboration deal with Beth Israel Deaconess Medical Center and a licensing agreement with Harvard University to develop CRISPR-Cas9-enhanced chimeric antigen receptor-engineered T-cell therapies for cancer. No financial details were disclosed.

Full Story: